Perceptive Advisors LLC Acadia Pharmaceuticals Inc Transaction History

Perceptive Advisors LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$20.78 - $31.77 $2.1 Million - $3.21 Million	101,000 New	101,000 $3.16 Million
Q2 2022 Aug 15, 2022	SELL	$13.01 - $27.22 $3.71 Million - $7.75 Million	-284,853 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$20.94 - $27.5 $27.2 Million - $35.7 Million	-1,299,199 Reduced 82.02%	284,853 $6.9 Million
Q4 2021 Feb 14, 2022	BUY	$16.79 - $27.09 $26.6 Million - $42.9 Million	1,584,052 New	1,584,052 $37 Million
Q2 2021 Aug 16, 2021	SELL	$19.4 - $27.42 $27.4 Million - $38.7 Million	-1,410,305 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$25.02 - $54.99 $35.3 Million - $77.6 Million	1,410,305 New	1,410,305 $36.4 Million
Q1 2020 May 15, 2020	SELL	$31.65 - $46.87 $356,252 - $527,568	-11,256 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$36.21 - $51.4 $407,579 - $578,558	11,256 New	11,256 $482,000
Q2 2019 Aug 14, 2019	SELL	$23.32 - $28.12 $347,398 - $418,903	-14,897 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$16.17 - $27.38 $240,884 - $407,879	14,897 New	14,897 $400,000
Q2 2018 Aug 14, 2018	SELL	$15.07 - $22.34 $4.14 Million - $6.14 Million	-275,000 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$22.47 - $32.33 $6.18 Million - $8.89 Million	275,000 New	275,000 $6.18 Million

279

156M

901K

314K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.76B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.